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Potential Mechanisms for Cancer Resistance in Elephants and Comparative
Cellular Response to DNA Damage in Humans
Abstract
Importance: Evolutionary medicine may provide insights into human physiology and pathophysiology,
including tumor biology.
Objective: To identify mechanisms for cancer resistance in elephants and compare cellular response to
DNA damage among elephants, healthy human controls, and cancer-prone patients with Li-Fraumeni
syndrome (LFS).
Design, Setting, and Participants: A comprehensive survey of necropsy data was performed across 36
mammalian species to validate cancer resistance in large and long-lived organisms, including elephants
(n = 644). The African and Asian elephant genomes were analyzed for potential mechanisms of cancer
resistance. Peripheral blood lymphocytes from elephants, healthy human controls, and patients with LFS
were tested in vitro in the laboratory for DNA damage response. The study included African and Asian
elephants (n = 8), patients with LFS (n = 10), and age-matched human controls (n = 11). Human samples
were collected at the University of Utah between June 2014 and July 2015.
Exposures
Exposures: Ionizing radiation and doxorubicin.
Main Outcomes and Measures: Cancer mortality across species was calculated and compared by body
size and life span. The elephant genome was investigated for alterations in cancer-related genes. DNA
repair and apoptosis were compared in elephant vs human peripheral blood lymphocytes.
Results: Across mammals, cancer mortality did not increase with body size and/or maximum life span
(eg, for rock hyrax, 1% [95% CI, 0%-5%]; African wild dog, 8% [95% CI, 0%-16%]; lion, 2% [95% CI, 0%-7%]).
Despite their large body size and long life span, elephants remain cancer resistant, with an estimated
cancer mortality of 4.81% (95% CI, 3.14%-6.49%), compared with humans, who have 11% to 25% cancer
mortality. While humans have 1 copy (2 alleles) of TP53, African elephants have at least 20 copies (40
alleles), including 19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse
transcription polymerase chain reaction. In response to DNA damage, elephant lymphocytes underwent
p53-mediated apoptosis at higher rates than human lymphocytes proportional to TP53 status (ionizing
radiation exposure: patients with LFS, 2.71% [95% CI, 1.93%-3.48%] vs human controls, 7.17% [95% CI,
5.91%-8.44%] vs elephants, 14.64% [95% CI, 10.91%-18.37%]; P < .001; doxorubicin exposure: human
controls, 8.10% [95% CI, 6.55%-9.66%] vs elephants, 24.77% [95% CI, 23.0%-26.53%]; P < .001).
Conclusions and Relevance: Compared with other mammalian species, elephants appeared to have a
lower-than-expected rate of cancer, potentially related to multiple copies of TP53. Compared with human
cells, elephant cells demonstrated increased apoptotic response following DNA damage. These findings,
if replicated, could represent an evolutionary-based approach for understanding mechanisms related to
cancer suppression.
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OBJECTIVE To identify mechanisms for cancer resistance in elephants and compare cellular
response to DNA damage among elephants, healthy human controls, and cancer-prone
patients with Li-Fraumeni syndrome (LFS).
DESIGN, SETTING, AND PARTICIPANTS A comprehensive survey of necropsy data was
performed across 36 mammalian species to validate cancer resistance in large and long-lived
organisms, including elephants (n = 644). The African and Asian elephant genomes were
analyzed for potential mechanisms of cancer resistance. Peripheral blood lymphocytes from
elephants, healthy human controls, and patients with LFS were tested in vitro in the
laboratory for DNA damage response. The study included African and Asian elephants
(n = 8), patients with LFS (n = 10), and age-matched human controls (n = 11). Human samples
were collected at the University of Utah between June 2014 and July 2015.
EXPOSURES Ionizing radiation and doxorubicin.
MAIN OUTCOMES AND MEASURES Cancer mortality across species was calculated and
compared by body size and life span. The elephant genome was investigated for alterations in
cancer-related genes. DNA repair and apoptosis were compared in elephant vs human
peripheral blood lymphocytes.
RESULTS Across mammals, cancer mortality did not increase with body size and/or maximum
life span (eg, for rock hyrax, 1% [95% CI, 0%-5%]; African wild dog, 8% [95% CI, 0%-16%];
lion, 2% [95% CI, 0%-7%]). Despite their large body size and long life span, elephants remain
cancer resistant, with an estimated cancer mortality of 4.81% (95% CI, 3.14%-6.49%),
compared with humans, who have 11% to 25% cancer mortality. While humans have 1 copy
(2 alleles) of TP53, African elephants have at least 20 copies (40 alleles), including 19
retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse
transcription polymerase chain reaction. In response to DNA damage, elephant lymphocytes
underwent p53-mediated apoptosis at higher rates than human lymphocytes proportional to
TP53 status (ionizing radiation exposure: patients with LFS, 2.71% [95% CI, 1.93%-3.48%] vs
human controls, 7.17% [95% CI, 5.91%-8.44%] vs elephants, 14.64% [95% CI,
10.91%-18.37%]; P < .001; doxorubicin exposure: human controls, 8.10% [95% CI,
6.55%-9.66%] vs elephants, 24.77% [95% CI, 23.0%-26.53%]; P < .001).
CONCLUSIONS AND RELEVANCE Compared with other mammalian species, elephants
appeared to have a lower-than-expected rate of cancer, potentially related to multiple copies
of TP53. Compared with human cells, elephant cells demonstrated increased apoptotic
response following DNA damage. These findings, if replicated, could represent an
evolutionary-based approach for understanding mechanisms related to cancer suppression.
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Potential Mechanisms for Cancer Resistance in Elephants vs Humans

T

he mechanisms that prevent accumulation of genetic
damage and subsequent uncontrolled proliferation
of somatic cells in multicellular organisms remain
poorly understood. A greater number of cells and cell divisions increases the chance of accumulating mutations resulting in malignant transformation.1 If all mammalian cells are
equally susceptible to
AV annexin V
oncogenic mutations,
LFS Li-Fraumeni syndrome
then cancer risk should
increase with body size
Mdm2 mouse double minute
2 homolog
(number of cells) and
PBL peripheral blood lymphocyte
species life span (number
of cell divisions). The
PI propidium iodide
Peto paradox describes
the observation that cancer incidence across animals does
not appear to increase as theoretically expected for larger
body size and life span.2,3 To our knowledge, the cellular
mechanism for this phenomenon of cancer resistance has
never been demonstrated experimentally in organisms other
than rodents.4-6
TP53 (encoding the protein p53 [RefSeq NM_000546]) is
a crucial tumor suppressor gene, mutated in the majority of
human cancers. 7 Referred to as the “guardian of the
genome,” inactivation of p53 leads to 3 cancer cell characteristics including suppression of apoptosis, increased proliferation, and genomic instability. 8,9 Humans contain 1 copy
(2 alleles) of TP53, and both functioning alleles are crucial to
prevent cancer development. Absence of 1 functional allele
leads to Li-Fraumeni syndrome (LFS), a cancer predisposition with more than a 90% lifetime risk for cancer, multiple
primary tumors, and early childhood cancers.10,11 Understanding the cellular mechanism of cancer suppression in
animals could benefit humans at high risk of cancer, such as
patients with LFS, and even the healthy, aging population.
This study investigated the cancer rate in different mammals (including elephants), identified potential molecular
mechanisms of cancer resistance, and compared response to
DNA damage in elephants with that in healthy human controls and individuals with LFS.

Methods
Ethical and scientific institutional review board approval was
obtained from each participating research organization for all
elephant and human participation, including written informed consent from human participants. Experiments were
performed on peripheral blood lymphocytes (PBLs) from
African and Asian elephants, from a representative clinical
cohort of patients with LFS enrolled in a separate study (the
Cancer Genetics Study, University of Utah), and from agematched human controls without a significant family history
of cancer also enrolled in the Cancer Genetics Study. Patients
with LFS were selected for inclusion as a representative sample
based on TP53 mutation status, varied cancer history, and availability for blood draw. Human subject materials were collected at the University of Utah from June 2014 to July 2015.
Laboratory experiments were also performed on African
jama.com
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elephant fibroblasts, human fibroblasts, and HEK293 cells to
confirm these findings.
Necropsy data were examined from zoo animals to
determine if empirical evidence supports that cancer incidence does not increase with body size or life span. Fourteen
years of necropsy data collected by the San Diego Zoo12 was
compiled and tumor incidence was calculated for 36 mammalian species, spanning up to 6 orders of magnitude in size
and life span.13 Data from the Elephant Encyclopedia14 were
analyzed on the cause of death in captive African (Loxodonta
africana) and Asian (Elephas maximus) elephants to estimate
age incidence and overall lifetime cancer risk. Using the
cancer transformation model from Calabrese and Shibata,15
the percentage decrease in cellular mutation rate was calculated to account for a 100× increase in cell mass (the difference between elephants and humans) without cancer
development.
Genomic sequence analysis was next performed on the
publicly available scaffolds of the African elephant genome in
the Ensembl database (release 72; http://www.enssemble
.org/) and the NCBI Gene database (http://www.ncbi.nlm.nih
.gov/gene), with examination of cancer-related genes including oncogenes and tumor suppressors. TP53 sequence
alignments were explored in related species, and African and
Asian elephant TP53 retrogenes were cloned and resequenced. Capillary sequencing was performed on single elephants to avoid issues of single-nucleotide polymorphisms
between elephants. Whole genome sequencing (Illumina HiSeq
2500) was performed on freshly extracted DNA from an African
elephant at 40× average sequence coverage, with more than
100× coverage within areas of TP53.
Functional molecular analysis of TP53 and its retrogenes
was performed on peripheral blood mononuclear cells from
African and Asian elephants and fibroblasts from an African
elephant. To determine if TP53 retrogenes are expressed in
the elephant, reverse transcription–polymerase chain reaction was performed on RNA collected from African elephant
peripheral blood mononuclear cells and African elephant
fibroblasts. Polymerase chain reaction primers were
designed to distinguish the TP53 retrogenes from the ancestral sequence and splice variants. Human vs elephant DNA
repair efficiency (measured by double-strand breaks indicated by number of phospho-histone H2AX [pH2AX] foci),
apoptosis (annexin V [AV] and propidium iodide [PI] by flow
cytometry and Apotox-Glo, Promega), and cell cycle arrest
(Apotox-Glo, Promega) were compared at different time
points (1, 5, 10, 18, 24, and 72 hours) after DNA damage
(doxorubicin, 0.005-30 μM; and ionizing irradiation, 0.5, 2,
5, 6, 10, and 20 Gy). Late apoptosis was defined as AV+PI+
and early apoptosis was defined as AV+PI−. Experiments
were performed in either triplicate or quadruplicate. p53
plays a critical role in p21 and mouse double minute 2 homolog (Mdm2 or E3 ubiquitin-protein ligase Mdm2) protein
induction following DNA damage,16,17 so p21 immunoblots
were performed to validate a p53-dependent DNA damage
response in elephant cells. p53 retrogene 9 (GenBank
KF715863) was cloned into an expression vector to produce a
protein fused to an epitope from the Myc protein. HEK293
(Reprinted) JAMA November 3, 2015 Volume 314, Number 17
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Figure 1. Cancer Incidence Across Species by Body Size and Life Span
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The mammalian species studied span the striped grass mouse to the elephant.
Cancer incidence is not associated with mass and life span, as shown by the
logistic regression (model fit shown as blue line; 95% CIs shown as dashed
lines). Each data point in the graph is supported by a minimum of 10 necropsies
for the included mammals (San Diego Zoo) and 644 annotated deaths for

cells were transfected with this Myc-tagged p53 retrogene 9
expression vector and p53 retrogene protein expression was
measured by immunoblot using an antibody to the Myc tag.
Retrogene protein product was co-immunoprecipitated from
HEK293 cell lysates with Myc antibody, followed by immunoblots for phospho-p53 (serine-15) and Mdm2. The HEK293
cell line was chosen for these experiments because it is a
human cell line (human embryonic kidney) that is easy to
transfect and measure protein expression.
Cross-species lifetime cancer incidence was estimated by
the number of animals in each species that reportedly died of
cancer. A logistic regression model was fit to determine if body
mass and maximum life span are variables associated with cancer incidence (R software, version 3.2.1). Additionally, all combinations of mass, life span, and mass-specific basal metabolic rate were examined for evidence of cancer association.
An inverse cancer association was specifically tested in the largest existing terrestrial mammal, the elephant. For the DNA
damage analysis, a χ2 test was used to compare pH2AX foci,
and an unpaired 2-sided t test with α = .05 was used for apoptosis and cell cycle arrest (R software, version 3.2.1, and GraphPad Prism, version 6.0e). Both a linear regression and a Jonckheere-Terpstra test were used to assess if apoptotic response
decreased with age.
Details of the experimental methods are further described in the eAppendix in the Supplement.
1852

elephants (Elephant Encyclopedia database). The risk of cancer depends on
both the number of cells in the body and the number of years over which those
cells can accumulate mutations; therefore, cancer incidence is plotted as a
function of mass × life span. All data with 95% CIs are presented in eTable 1 in
the Supplement.

Results
Zoo Necropsies and Cancer Mortality
The 36 mammalian species analyzed spanned from the
striped grass mouse (weight, 51 g, with a maximum life span
of 4.5 years) to the elephant (weight, 4800 kg, with a maximum life span of 65 years). Cancer risk did not increase with
mammalian body size and maximum life span among 36
species analyzed (eg, for rock hyrax, 1% [95% CI, 0%-5%];
African wild dog, 8% [95% CI, 0%-16%]; lion, 2% [95% CI,
0%-7%]) (Figure 1). No significant relationship was found
with any combinations of mass, life span, and basal metabolic rate and cancer incidence (eFigure 1 and eTable 1 in the
Supplement). Among 644 annotated elephant deaths
from the Elephant Encyclopedia database, the lifetime
cancer incidence was 3.11% (95% CI, 1.74%-4.47%) (Table 1).
To obtain a more conservative estimate, an inferred cancer
incidence was calculated for cases that lacked adequate
details for the cause of death, leading to an estimated
elephant cancer mortality rate of 4.81% (95% CI, 3.14%6.49%). Based on an algebraic model of carcinogenesis,15
a 2.17-fold decrease in mutation rate was calculated as
sufficient to protect elephants from cancer development
given their 100× increased cellular mass compared with
humans.

JAMA November 3, 2015 Volume 314, Number 17 (Reprinted)
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Table 1. Cause of Death in 644 Elephantsa
No. of Elephants

a

Age
Range, y

Total
Necropsies

Euthanized,
Noncancer

Noncancer
Disease

Exogenous
Mortality

Euthanized,
Unspecified

0-5

125

15

77

28

1

2

0

2

1.60 (0.00-4.24)

2.40 (0.00-5.44)

6-15

83

20

36

19

4

1

1

2

3.61 (0.00-8.02)

6.02 (0.58-11.47)

16-25

121

35

48

25

7

2

2

2

3.31 (0.00-6.69)

4.96 (0.86-9.05)

26-35

108

27

51

15

8

4

3

0

2.78 (0.00-6.11)

3.70 (0.00-7.60)

36-45

94

32

27

13

12

5

0

5

5.32 (0.47-10.16) 6.38 (1.18-11.58)

46-55

70

14

23

7

7

17

1

1

2.86 (0.00-7.37)

5.71 (0.00-11.59)

≥56

43

3

7

6

7

19

1

0

2.33 (0.00-8.16)

6.98 (0.00-15.29)

Lifetime, 644
0-≥56

146

269

113

46

50

8

12

3.11 (1.74-4.47)

4.81 (3.14-6.49)

Observed cancers are reported as the percentage of deaths annotated as
being caused by cancer or by euthanasia due to cancer. Inferred cancer risk
assumes that cancer occurs at the same fraction of deaths in cases with

African Elephant Genome Analysis
The African elephant (L africana) draft genome LoxAfr3 contains 19 copies of TP53. The human haploid genome contains 1 copy of TP53, while Ensembl and GenBank annotate a
large number of TP53 paralogs in the African elephant
genome (12 and 20 haploid copies, respectively; eTable 2 in
the Supplement). Elephant sequence alignments revealed 1
TP53 copy with a comparable gene structure to TP53 found
in other mammalian species (ancestral copy). The other 19
copies lack true introns, suggesting that they originated
from retrotransposition (retrogenes). Cloning and resequencing confirmed at least 18 distinct retrogene copies in
the African elephant in a maximum likelihood phylogeny,
supported by multiple clones clustered into 2 main subtrees
(groups A and B; Figure 2). Whole-genome sequencing with
deep coverage confirmed 1 ancestral copy and 19 total retrogene copies, similar to the TP53 20 total copies annotated in
GenBank. Eleven of the 18 retrogenes from the capillary
sequencing were similar but not identical to previous GenBank annotations and local whole genome sequencing data
(eTable 2 in the Supplement). High variance in coverage
across reference TP53 copies may indicate additional TP53
elephant copies not yet successfully assembled. There was
no evidence for 8 of the published retrogene copies, possibly
because of undersampling of clones, misassembly in the
published genome, or differences between individual
elephants. An additional 7 cloned sequences had support
from multiple clones but were not found in either database.
Further TP53 copies in the genome may also have been
undetected by the polymerase chain reaction primers. The
Asian elephant DNA was also found to contain 15 to 20 copies of group A and B TP53 retrogenes (eFigure 2 in the
Supplement).

TP53 Retrogene Transcription and Translation
Reverse transcription–polymerase chain reaction on RNA
from African elephant peripheral blood mononuclear cells
and fibroblasts exposed to 2 Gy of radiation demonstrated
TP53 retrogene expression. Products of the expected sizes
were observed, separating the 2 groups of retrogenes (eFigjama.com

Disease,
Unspecified

Euthanized,
Cancer

Cancer Observed % With
Cancer (95% CI)

Inferred % With
Cancer (95% CI)

unspecified causes as those with specified causes. Exogenous causes of
mortality include accidents (eg, falling in the enclosure) and animal fights that
cause fatal injury.

ure 3 in the Supplement). Sanger sequencing confirmed their
identities as retrogenes from group A and/or group B (eFigure
4 in the Supplement). Transfected HEK293 cells showed p53
retrogene 9 protein expression by immunoblotting that
increased with DNA damage similar to p53 in human fibroblasts exposed to DNA damage (eFigure 5, A-B, in the Supplement). Co-immunoprecipitation of lysates from the transfected HEK293 cells exposed to 6 Gy of ionizing radiation
displayed phosphorylation of the Myc-tagged p53 elephant
retrogene at serine-15 along with 90 kDa Mdm2, indicating
Mdm2 binding (eFigure 5C in the Supplement).

Elephant Cell Response to DNA Damage
Lymphocytes undergo p53-dependent apoptosis in response
to DNA damage,18,19 while fibroblasts undergo both p53dependent apoptosis and cell cycle arrest, 20-22 and both
elephant cell types were tested accordingly. African elephant
PBLs demonstrated apoptosis at significantly elevated rates
compared with human PBLs after 18 hours when exposed to
2 Gy of ionizing radiation (late apoptosis: 33.20% [95% CI,
28.31%-38.09%] vs 14.07% [95% CI, 13.13%-15.01%];
P < .001; early apoptosis: 21.07% [95% CI, 19.61%-22.52%] vs
11.73% [95% CI, 11.35%-12.11%]; P < .001) (Figure 3, A-C) and
when exposed to 5 μM of doxorubicin (24.77% [95% CI,
23.0%-26.53%] vs 8.10% [95% CI, 6.55%-9.66%]; P < .001)
(eFigure 6 in the Supplement). Peripheral blood lymphocytes from individuals with LFS (n = 10), healthy controls
(n = 10), and 1 African elephant (tested in 3 independent
experiments) treated with 2 Gy of ionizing radiation revealed
different levels of apoptosis (apoptosis calculated at 18 hours
by subtracting the percentage of AV+PI+ cells treated with 2
Gy of ionizing radiation from the percentage of AV+PI+ cells
cultured without treatment). Cells of patients with LFS
underwent significantly less apoptosis (2.71%; 95% CI,
1.93%-3.48%) compared with healthy human PBLs (7.17%;
95% CI, 5.91%-8.44%; P < .001) and elephant PBLs (14.64%;
95% CI, 10.91%-18.37%; P < .001) (Figure 4 and eTable 3 in
the Supplement).
No significant difference was detected in pH2AX foci
following ionizing radiation between human and elephant
(Reprinted) JAMA November 3, 2015 Volume 314, Number 17
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Figure 2. Group A and Group B TP53 Retrogenes in the African Elephant
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A maximum likelihood phylogeny was used to cluster the sequenced TP53
retrogene clones and to confirm the number of unique genes uncovered in the
African elephant genome. The phylogeny allows for visualization of TP53
retrogene similarity to one another as well as their relationship to the ancestral
TP53 sequence in the elephant and hyrax. The capillary sequenced clones from
this study are shown as black circles and published sequences from GenBank
are shown as red squares. Gene identifiers and genomic coordinates are given in
eTable 2 in the Supplement. Phylogenic analysis reveals at least 18 distinct
clusters of processed TP53 copies (shown as colored blocks numbered 1 to 18).
These clusters fall into 2 groups, labeled group A and group B. The branch

1854

labeled “elephant” is the coding sequence of the ancestral TP53, and “hyrax”
represents the coding sequences from the hyrax TP53. The hyrax, on the upper
left, is used as the outgroup to show that the hyrax and elephant ancestral TP53
sequences are more similar to each other than to the retrogenes, and also that
the retrogenes evolved after the split between hyrax and elephant. The
distances between the retrogene sequences display their relationship based on
sequence similarity but do not represent precise evolutionary time estimates.
These data were generated with DNA from 1 elephant to control for
polymorphic bases between individual elephants.
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Figure 3. African Elephant and Human Peripheral Blood Lymphocytes and Sensitivity to Ionizing Radiation
A Lymphocytes in late apoptosis after ionizing radiation treatment
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a

P < .001.

b

Panel A: NT at 10 hours, P = .008.
Panel B: NT at 0 hours, P = .002;
2 Gy at 5 hours, P = .003; 6 Gy at
5 hours, P = .004.

c

P = .03.

AV+PI–
11.7

Annexin V

PBLs, indicating that the increased apoptosis in elephants
c annot be attributed to more DNA damage (Table 2,
Figure 5, and eFigure 7 in the Supplement). This increased

A, The percentage of late apoptosis
(annexin V positive [AV+] and
propidium iodide positive [PI+]) and
B, early apoptosis (AV+PI−) in
elephant peripheral blood
lymphocytes compared with human
peripheral blood lymphocytes in
response to 2 Gy and 6 Gy of ionizing
radiation are graphed. Significant
differences computed with a 2-sided
t test between human and elephant
at 0, 5, 10, 18, and 24 hours are
indicated. Error bars represent 95%
CIs. C, Representative scatter plots
from flow cytometry are shown from
the 0- and 18-hour time points. NT
indicates no treatment.

apoptosis was observed in different lymphocyte wash conditions (eFigure 8 in the Supplement). Unlike increasing
TP53 mRNA levels seen in human PBLs after ionizing radia(Reprinted) JAMA November 3, 2015 Volume 314, Number 17
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tion, gene expression of ancestral and retrogene TP53 did
not increase in elephant PBLs (eFigure 9 in the Supplement). Both elephant and human PBLs showed p53 and p21
protein expression following ionizing radiation exposure
(Figure 6). More p21 protein expression was observed at 5
hours in elephant PBLs treated with 0.5 Gy of ionizing radiation (20.1-fold increase; 95% CI, 8.72- to 31.5-fold) compared with human PBLs (3.5-fold increase; 95% CI, 1.7- to
5.31-fold; P = .004) (eFigure 10, A-B, in the Supplement).
Elephant fibroblasts also showed increased p21 protein
expression following 2 Gy of ionizing radiation at 5 hours
(1.9-fold increase) compared with no increase in human
Figure 4. Apoptosis Response Relative to Number of Copies of TP53
Individuals with Li-Fraumeni syndrome
c.530C>G (R248W mutation)
del exon 1
c.586C>T (A347D mutation)
c.1040C>A (P177R mutation)
c.751A>C (A347D mutation)
c.742C>T (R248W mutation)
c.580C>T (P177R mutation)

20

AV+PI+ Cells, Mean %

15

10

5

0

Individuals With
Li-Fraumeni
Syndrome
1 TP53 allele

Healthy Human
Controls

Elephant
40 TP53 alleles

2 TP53 alleles

Percentage of apoptosis is shown for peripheral blood lymphocytes treated
with 2 Gy of ionizing radiation from 10 individuals with Li-Fraumeni syndrome
(with 1 functioning TP53 allele), 10 healthy controls (with 2 TP53 alleles), and
1 African elephant tested in 3 independent experiments (with 40 TP53 alleles).
Ionizing radiation–induced apoptosis increased proportionally with additional
copies of TP53 and inversely correlated with cancer risk. Experiments
performed in quadruplicate for each individual and each colored box represents
the mean percentage of cells in late apoptosis as measured by flow cytometry
(percentage of annexin V–positive [AV+] and propidium iodide–positive [PI+]
treated cells minus AV+PI+ untreated cells). The healthy control lymphocytes
underwent more apoptosis than those from LFS patients (P < .001),
and elephant lymphocytes underwent more apoptosis than those from
healthy controls (P < .001 by 2-sided t test). Horizontal lines indicate
the combined mean for all data points in each group with error bars
indicating 95% CIs.

fibroblasts (eFigure 10C in the Supplement). Similar to lymphocytes, elephant vs human fibroblasts showed evidence
of increased apoptosis after 10 μM of doxorubicin as measured by increased caspase activity relative to dimethyl
sulfoxide–treated fibroblasts (elephant: 9.1-fold increase
[95% CI, 7.93- to 10.25-fold] vs human: 2.24-fold increase
[95% CI, 1.5- to 2.98-fold]; P < .001) and additionally
showed reduced viability consistent with cell cycle
arrest after 0.5 Gy of ionizing radiation (elephant: 80.81%
[95% CI, 68.86%-92.75%] vs human: 95.87% [95% CI,
90.73%-101.0%]; P = .01) (eFigure 11 in the Supplement;
some of the elephant fibroblast experiments do not
have P values because they were designed to demonstrate
p21 protein expression and not powered for statistical
comparison).
As a post hoc analysis, the same experiments were repeated in PBLs from multiple Asian elephants (n = 6) of different ages (2, 12, 17, 38, 57, and 69 years old). Asian elephant
lymphocytes also demonstrated an increased rate of apoptosis (50.63%; 95% CI, 41.71%-59.53%) relative to human cells
(23.67%; 95% CI, 21.18%-26.15%; P < .001) when exposed to 2
Gy of ionizing radiation (18-hour culture) and an increase in
p21 expression (Figure 7, A-B). Additionally, the apoptotic response in PBLs decreased with the age of Asian elephants when
tested with both a linear regression and a JonckheereTerpstra test, which allows for nonlinear relationships
(Figure 7C) (2-year-old elephant with 2 Gy radiation at 18 hours,
52.53% [95% CI, 35.86%-69.2%] and 69-year-old elephant,
40.03% [95% CI, 30.64%-49.43%]; P = .002 by linear regression; P < .001 by Jonckheere-Terpstra test). These agerelated results should be interpreted as exploratory and hypothesis generating.

Discussion
Peto first made the observation more than 35 years ago that
larger and longer-lived mammals develop less cancer than
expected,3,23,24 but the evolutionary and functional mechanisms for this phenomenon have been studied only in
rodents.4-6 To our knowledge, this study offers the first supporting evidence based on empirical data that larger animals
with longer life spans may develop less cancer, especially
elephants. The cancer mortality rate for elephants was found

Table 2. pH2AX Foci in Human and African Elephant Cells After 2 Gy of Ionizing Radiationa
Viable Cells With Indicated No. of pH2AX Foci, %
0-5 Foci

a
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6-10 Foci
Human

11-15 Foci
Elephant

Human

16-≥20 Foci

Treatment and Time Frame

Human

Elephant

Elephant

No treatment, 1 h

97.3

98.7

2.7

1.3

0.0

0.0

Human
0.0

Elephant
0.0

No treatment, 5 h

97.7

98.0

2.3

1.3

0.0

0.7

0.0

0.0

No treatment, 24 h

99.7

99.7

0.3

0.3

0.0

0.0

0.0

0.0

2 Gy, 1 h

23.0

26.3

25.3

33.7

19.0

17.0

32.7

23.0

2 Gy, 5 h

46.7

51.0

32.7

39.0

14.3

9.0

6.3

1.0

2 Gy, 24 h

94.3

92.3

5.3

7.3

0.3

0.0

0.0

0.0

Foci indicate remaining DNA double-stranded breaks. Cells are binned by the
number of phospho-histone H2AX (pH2AX) foci and demonstrate no

significant difference in the rate of DNA damage repair between human and
elephant (P > .05 by χ2 test).
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Figure 5. Visualization of Apoptosis and DNA Damage in Human and Elephant Cells After Ionizing Radiation
A African elephant PBLs 5 h after 2 Gy ionizing radiation

B

Human PBLs 5 h after 2 Gy ionizing radiation

DAPI, a nuclear stain that binds to
DNA (blue), and phospho-histone
H2AX foci (green) labeled peripheral
blood lymphocytes (PBLs) 5 hours
after 2 Gy of ionizing radiation show
similar amounts of DNA damage.
Apoptosis, rarely observed in the
human cells, is visualized in the
elephant cells (blue arrowheads
indicate apoptotic cells with DNA
fragmentation, identified by nuclear
blebbing). Images displayed at
40× magnification.

Figure 6. p21 and p53 Protein Expression After Ionizing Radiation
0h

5h
NT

2 Gy

24 h
6 Gy

NT

2 Gy

6 Gy
p53

African elephant PBLs

NT

p21

GAPDH

Human PBLs

p53

p21

GAPDH

to be less than 5% compared with a cancer mortality rate for
humans of 11% to 25%.25 Additionally, TP53 amplification
was identified in elephants, and the effect TP53 amplification
may have on apoptotic response to DNA damage was
explored. These findings support the concept of an
evolutionary-based approach for cancer suppression.
TP53 plays a central role in cancer suppression and
response to DNA damage through apoptosis and cell cycle
arrest.8,26,27 Patients with LFS inherit only 1 functioning
TP53 allele and may have a lifetime risk of cancer approaching 100%.10,11 Conversely, inserting additional copies of constitutively active TP53 in mice confers cancer resistance
with accelerated aging, 28 while redundant TP53 alleles
under the endogenous promoter generate cancer-resistant
laboratory mice that age normally.29 The evolution of the
elephant would have involved a strong selective pressure to
jama.com

Western blot at the indicated time
points after ionizing radiation shows
p21 and p53 protein expression in
elephant and human lymphocytes.
The p53 antibody detects only
nonphosphorylated protein.
GAPDH indicates glyceraldehyde
3-phosphate dehydrogenase,
a protein-loading control;
PBL, peripheral blood lymphocyte;
NT, no treatment.

naturally suppress cancer in a long-lived animal 100 000
times the size of a mouse. Female elephants reproduce and
raise offspring throughout their entire life span of 50 to 80
years, older males have higher status and more reproductive
opportunities,30 and herds with older matriarchs may have
higher fitness.31 The enormous mass, extended life span,
and reproductive advantage of older elephants would have
selected for an efficient and fail-safe method for cancer suppression. The multiple copies of TP53 and the enhanced
p53-mediated apoptosis observed in elephants may have
evolved to offer such cancer protection.
The data suggest a lower threshold for DNA damage
before triggering p53-dependent apoptosis in elephants than
in humans, a possible evolutionary strategy to avoid cancer
by efficiently removing mutant cells. Consistent with previous evidence that increasing TP53 gene dosage increases
(Reprinted) JAMA November 3, 2015 Volume 314, Number 17
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Figure 7. Asian Elephant Cells and DNA Damage Response
A Apoptotic lymphocytes 18 h after

B

ionizing radiation treatment
Human (aged 18 y)

AV+ Cells, %

Apoptotic lymphocytes 18 h after ionizing
radiation treatment (Asian elephants)

2 Gy, 5 h

No treatment
80

2 Gy

p53

b

60

40

No treatment

Asian elephant (aged 17 y)

60

a

AV+ Cells, %

80

C

p21 Protein expression
in Asian elephant lymphocytes

p21

20

40

20

GAPDH
0

0

No
Treatment

2

2 Gy

17

38

57

69

Age, y

A, An example is shown of percentage of annexin V–positive (AV+) (apoptotic)
lymphocytes from a 17-year-old Asian elephant compared with AV+
lymphocytes from an 18-year-old human 18 hours after ionizing radiation
exposure. Error bars represent 95% CIs and significant differences computed
with a 2-sided t test are indicated. B, Evidence of p21 protein expression is seen
5 hours after 2 Gy of ionizing radiation in Asian elephant lymphocytes.
C, The apoptotic response in Asian elephant lymphocytes is shown to decrease

transcriptional regulation of p53 target genes,17,27 apoptotic
rates in lymphocytes increased proportionally among
patients with LFS (1 TP53 functioning allele), human controls
(2 TP53 alleles), and elephants (40 TP53 alleles). Elephant
cells exposed to DNA damage showed increased p21 expression, a downstream target of p53 activation. Also, p53 retrogenes were up-regulated and translated when transfected
into human cells treated with ionizing radiation and doxorubicin. These combined observations suggest that the
increased cell death in elephants may be mediated by p53
and enhanced by the additional TP53 retrogenes.
Retrotransposed genes, often called pseudogenes, can
play functional roles in biology. 32,33 Based on the study
results, the TP53 retrogenes may functionally increase
elephant cell response to DNA damage by triggering p53dependent apoptosis rather than increasing DNA repair.
Apoptosis can prevent mutations from propagating to
future cell generations through removal of mutated clones.
The elephant cells appeared twice as sensitive to DNA
damage–induced apoptosis as human cells. Increasing
apoptosis effectively lowers the ongoing mutation rate for
the entire cell population and, as calculated, this 2-fold
decrease in the somatic mutation rate (doubling of apoptosis) in elephants could explain the 100× increase in cell
mass without c ancer transformation. 1 5 , 3 4 The Asian
elephant genome contained 15 to 20 TP53 retrogene copies,
suggesting that TP53 retrogene amplification predated the
split of the African and Asian elephant species approximately 6.6 million to 8.8 million years ago. 35 The hyrax
(Procavia capensis) is the closest elephant relative with an
available genome assembly (proCap1) and contains only 1
copy (2 alleles) of TP53. The hyrax and elephant lineages
diverged 54 million to 65 million years ago,36 making this
time frame the upper bound of when these TP53 retrogenes
evolved.
1858

12

with age (P = .002 by linear regression and P < .001 by Jonckheere-Terpstra
tests). A single elephant of each indicated age was tested in triplicate.
GAPDH indicates glyceraldehyde 3-phosphate dehydrogenase,
a protein-loading control.
a

P = .006.

b

P < .001.

A consistent age-related decrease in apoptosis was found
in Asian elephants. Age-related decline in apoptotic response
has been observed in murine T cells,37 human PBLs,38 and human sperm.39 Young elephants rapidly grow in less than 10
years from a birth weight of 100 kg to more than 3000 kg at
reproductive age, a 30-fold increase in cellular mass with more
than 1 kg of weight gain per day. Such a high rate of cell division and expansion in the growing elephant requires an especially efficient system of cancer prevention.
The study of cancer and apoptosis across species has
several limitations. Cancer mortality rates in humans are
often reported as deaths per 100 000 per year,25 and sufficient sample sizes of animals are difficult to find for comparison. The cross-species mortality rates in this study
included estimates based on small numbers of captive animals with wide confidence intervals. More data need to be
collected to confidently demonstrate the absence of correlation of mass and life span with cancer mortality. Environmental factors also play a role in cancer development, and it
is unclear how captivity influences cancer rates through
diet, stress, physical activity, and reproduction. The
expected life span of captive African and Asian elephants is
decreased,40 and this analysis may not have fully captured
the elderly elephant population most expected to develop
cancer. Adding to the complexity, humans are treated with
modern medicine and may have an artificially extended life
span, which, along with carcinogenic exposures like smoking, increases the lifetime risk of cancer death. Neither the
African nor Asian elephant genome has been formally
assembled and, consequently, elephant-specific molecular
agents such as phosphorylated p53 elephant antibodies to
measure elephant p53 activation are challenging to obtain.
Studying the p53 pathway requires certain assumptions,
such as that p21 and Mdm2 protein levels truly reflect p53
activity, as they do in humans. Although the data are sug-
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gestive, it is still unknown if elephant TP53 retrogenes produce functional protein. These retrogenes may serve as
either functional or nonfunctional protein decoys for degradation (eFigure 12 in the Supplement), explaining the
co-immunoprecipitation of Mdm2 with TP53 elephant retrogenes. With further assembly of the elephant genome,
future experiments with genomic technologies like RNA
sequencing will prove helpful in understanding the functional differences reflected in the increased apoptosis found
in elephants.

Preliminary Communication Research

Conclusions
Compared with other mammalian species, elephants appeared to have a lower-than-expected rate of cancer, potentially related to multiple copies of TP53. Compared with human cells, elephant cells demonstrated increased apoptotic
response following DNA damage. These findings, if replicated, could represent an evolutionary-based approach for understanding mechanisms related to cancer suppression.
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